Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials

Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials

Immune checkpoint inhibitors (ICIs) are recommended as first-line treatment for late-stage non-small cell lung cancer (NSCLC), either as monotherapy or in combination with chemotherapy. However, efficacy and safety comparisons between ICIs as monotherapy and ICIs with chemotherapy are lacking. We se...

Full description

Bibliographic Details
Main Authors: Xiang Li, Shi Yan, Jichun Yang, Yaqi Wang, Chao Lv, Shaolei Li, Jun Zhao, Yue Yang, Minglei Zhuo, Nan Wu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-01-01
Series:Frontiers in Oncology
Subjects:
PD-1/PD-L1 inhibitors
late-stage non-small cell lung cancer
PD-L1 expression level
survival efficacy
safety
first line treatment
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.574752/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.574752/full

Similar Items